A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis

This is a phase II, multicentre, randomized, two-arm blinded study with an open label calibrator arm in adults and adolescents (≥12 years) with confirmed primary VL.

Study Overview

• Status: Recruiting
• Conditions: Primary Visceral Leishmaniasis
• Intervention / Treatment: Drug: LXE408; Other: Placebo; Drug: AmBisome®

Detailed Description

This study is run by DNDi with Novartis as co-development partner

• Study Type: Interventional
• Enrollment (Estimated): 105
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Gwen Carn; Phone Number: +41 79 799 3886; Email: gcarn@dndi.org

Study Locations

• India
  • Bihar, India
    • Recruiting
    • DrugsNeglectedD Investigational Site
  • Patna, India
    • Recruiting
    • DrugsNeglectedD Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Male and female patients ≥ 18 years (at the time of the screening visit) who are able to comply with the study protocol. Following a favourable interim analysis result, patients ≥12 <18 years will also be enrolled in the trial
• Patients for whom written informed consent has been obtained (if aged 18 years and over) or signed by parent(s) or legal guardian for patients under 18 years of age. In the case of minors, assent from the child also needs to be obtained
• Primary symptomatic VL (defined as typical parameters including, but not limited to, fever for > 2 weeks, weight loss, and splenomegaly)
• Visualization of Leishmania amastigotes by microscopy in tissue samples (spleen or bone marrow)

Exclusion Criteria:

• Clinical signs of severe VL (jaundice, spontaneous bleeding, edema, ascites, coma, organ failure)
• Laboratory abnormalities including ALT/SGPT > 3 times ULN, total bilirubin > 1.5 times ULN, creatinine >1.5 times ULN, amylase or lipase > 1.5 times ULN, haemoglobin < 6 g/dL or other clinically significant abnormal laboratory parameters which, in the opinion of the investigator, may indicate severe VL
• Patients with history of previous leishmaniasis and confirmed relapse
• Patients with para-kala-azar dermal leishmaniasis
• Patients with severe malnutrition (for children ≥12-<18 years: BMI-for-age WHO reference curves by sex, z score < -3; for adults ≥18 years: BMI < 16)
• History of congenital or acquired immunodeficiency, including positive HIV (test at screening)
• Known hypersensitivity to amphotericin B deoxycholate or any other constituents of AmBisome®
• Concomitant infections such as tuberculosis, severe malaria, or any other serious underlying disease that may interfere with the disease assessment (e.g., cardiac, renal, hepatic, haematologic, and pancreatic)
• Infection with hepatitis B (HBV) or hepatitis C virus (HCV). A positive HBV surface antigen (HBsAg) test, or if standard local practice, a positive HBV core antigen test, excludes a subject. Patients with a positive HCV antibody test should have HCV RNA levels measured. Patients with positive (detectable) HCV RNA should be excluded.
• Pregnant or nursing (lactating) women
• Women of childbearing potential who do not accept to have a pregnancy test done at screening and/or who do not agree to use highly effective contraception while taking the investigational drug and for 5 half-lives or 5 days, whichever is longer, after stopping the investigational drug.
• Sexually active males unwilling to use a condom during intercourse while taking the investigational drug and for 5 half-lives or 5 days, whichever is longer, after stopping the investigational drug.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LXE408 short regimen; LXE408 once daily for seven days (followed by 7 days of placebo).	Drug: LXE408; Film-coated tablets; Other: Placebo; Placebo film-coated tablets
Experimental: LXE408 long regimen; LXE408 once daily for 14 days	Drug: LXE408; Film-coated tablets
Active Comparator: Standard of care; AmBisome® 10 mg/kg IV single dose (SDA)	Drug: AmBisome®; Sterile lyophilised powder in a 15 mL sterile clear glass vial

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of patients with initial cure at Day 28 for LXE408	Initial cure defined as clinical improvement of Visceral leishmaniasis (VL), absence of parasites in the spleen or bone marrow (microscopy), and no rescue therapy on or before Day 28.	Day 28

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of patients with initial cure at Day 28 for AmBisome®	Initial cure defined as clinical improvement of Visceral leishmaniasis (VL), absence of parasites in the spleen or bone marrow (microscopy), and no rescue therapy on or before Day 28.	Day 28
Proportion of patients with definitive cure at Day 180 for LXE408 and AmBisome®	Definitive cure described as initial cure at Day 28, no requirement for rescue treatment throughout the study, no death associated to VL and absence of any clinical parameters of VL at Day 180.	Day 180
Mortality	All-cause mortality and mortality not associated with Visceral leishmaniasis (VL)	Days 28 and 180
Cmax for LXE408	Maximum Observed Blood-drug Concentrations for LXE408	Days 1 and 7
Tmax for LXE408	Time to Reach Maximum Blood-drug Concentrations for LXE408	Days 1 and 7
AUCtau for LXE408	Area Under The Plasma Concentration-time Curve Over A Dosing Interval for LXE408	Days 1 and 7
CLss/F for LXE408	Apparent Clearance for LXE408	Days 1 and 7
Cmax for Amphotericin B	Maximum Observed Blood-drug Concentrations for Amphotericin B	Days 1 and 7
AUC0-24h for Amphotericin B	Area under the plasma concentration-time curve from time zero to 24h for Amphotericin B	Day 1
AUC0-infinity for Amphotericin B	Area under the plasma concentration-time curve from time zero to infinity for Amphotericin B	Day 1
Blood parasite clearance	Blood parasite clearance over time, as measured by quantitative polymerase chain reaction (qPCR) from blood samples at defined time points and at any suspicion of relapse during the trial.	Baseline and Days 1, 3, 5, 7, 10, 14, 28 and 56
Proportion of patients with a positive loop-mediated isothermal amplification (LAMP) from blood samples	Proportion of patients with a positive loop-mediated isothermal amplification (LAMP) from blood samples at defined time points and at any suspicion of relapse during the trial.	Baseline and Days 28 and 56
Tissue parasite loads	Tissue parasite loads, as measured by qPCR from tissue samples (spleen or bone marrow) collected at defined time points and at any suspicion of relapse during the trial.	Baseline and Day 28
Proportion of patients with a positive loop-mediated isothermal amplification (LAMP) from tissue samples	Proportion of patients with a positive loop-mediated isothermal amplification (LAMP) from tissue samples at defined time points and at any suspicion of relapse during the trial.	Baseline and Day 28

Collaborators and Investigators

• Sponsor: Drugs for Neglected Diseases
• Collaborators: Novartis Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (Actual): December 27, 2022
• Primary Completion (Estimated): January 2, 2025
• Study Completion (Estimated): January 2, 2025

Study Registration Dates

• First Submitted: October 20, 2022
• First Submitted That Met QC Criteria: October 20, 2022
• First Posted (Actual): October 25, 2022

Study Record Updates

• Last Update Posted (Estimated): February 29, 2024
• Last Update Submitted That Met QC Criteria: February 28, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Infections; Vector Borne Diseases; Parasitic Diseases; Protozoan Infections; Skin Diseases, Parasitic; Skin Diseases, Infectious; Euglenozoa Infections; Leishmaniasis; Leishmaniasis, Visceral; Anti-Infective Agents; Antifungal Agents; Antiprotozoal Agents; Antiparasitic Agents; Liposomal amphotericin B
• Other Study ID Numbers: DNDi-LXE408-01-VL; CLXE408A12201R (Other Identifier: Novartis Pharmaceuticals)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No